Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free …Wall Street JournalMORRIS PLAINS, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of …
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free …GlobeNewswire (press release)MORRIS PLAINS, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the devel…
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free …MarketWatchImmunomedics, Inc. (NASDAQ:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment …
The UK Rituximab Trial for MEProHealthNow, however, despite the power and control of the psychiatric lobby, thanks to Invest in ME and the invaluable support of Jonathan Edwards, Emeritus Professor of Connective Tissue Medicine at University College, L…
Rituximab shows long-term efficacy in antibody-associated vasculitismedwireNewsmedwireNews: A single course of rituximab is a viable alternative to conventional cyclophosphamide/azathioprine immunosuppression in patients with severe antineutrophil cyto…
Cancer Monoclonal Antibodies Market Forecast to 2017The Herald | HeraldOnline.comGlobal Cancer mAbs Market Outlook to 2017 7.1 Market Size 7.2 Cancer mAbs: Approval History and Market Share 7.3 Cancer mAbs: Current and Future Market Size 7.3.1 Avastin …
Lilly Phase III Candidate Meets Primary Endpoint of NSCLC Overall SurvivalGenetic Engineering NewsEnzastaurin reportedly failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of DLBCL …
|
Government of Ontario’s Ministry of Health Approval of the Reimbursement of …
Canada NewsWire (press release) 13, 2013 /CNW/ – The Canadian Pemphigus and Pemphigoid Foundation (CPPF) applauds the Government of Ontario’s Ministry of Health and Long-Term Care decision to fund Rituxan (Rituximab) for the treatment of Pemphigus Vulgaris through the Ontario … |
|
EU5 rheumatologits rate Rituxan and Benlysta for Lupus
The Pharma Letter Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give Roche (ROG: SIX)/Genentech/Biogen Idec’s (Nasdaq: BIIB) Rituxan (rituximab) and GlaxoSmithKline (LSE: GSK)/Human Genome Sciences’ Benlysta … |
|
Burkitt Lymphoma Survival Improves For Some
Insciences Organisation The same regimen of intensive chemotherapy and the monoclonal antibody rituximab are recommended for most patients. “There was little available for Burkitt lymphoma in terms of prognostic factors, indicators, or scoring,” said Dr. Jorge Castillo … |